Biomarker Research in Musculoskeleton Disease

描述（由申请人提供）：骨质疏松症是老年男性和女性的一个重要问题。最近的研究表明，骨骼生物标志物可能提供有关骨质疏松症生物学原因的重要信息，并且可能有助于单独预测骨折或与其他危险因素结合。为了延长他正在进行的nih资助的生物标志物和骨骼脆弱性研究，加州大学旧金山分校医学、流行病学和生物统计学教授Douglas Bauer博士正在申请更新他的K24患者导向研究中期研究者奖，其科学目标是利用来自老年男性（mro）的纵向队列数据开发新的临床有用的蛋白质组学生物标志物。利用正在进行的骨折评估和最近对基线收集的血清蛋白质组学测量的资助，本研究将探讨3000名mri参与者的蛋白质组学特征与椎体骨折事件之间的潜在关系。通过与旧金山协调中心的长期合作，鲍尔博士将利用这些数据和其他来自多个大型研究的数据，继续指导对临床研究感兴趣的年轻研究人员，特别是住院医生。凭借最初的K24奖，鲍尔博士指导了现在正在追求额外研究培训和学术生涯的住院医生和研究员。与加州大学旧金山分校临床和转化科学研究所合作，在最初的K24奖期间，他还开发并指导了一个新的综合住院研究项目。这个新项目的目标是通过为住院医生提供正式的研究方法指导、试点资金和参与指导研究项目的机会来促进临床研究事业。K24奖的延续对于保护Bauer博士的时间，使他能够继续为与生物标志物和骨骼脆弱性相关的以患者为导向的研究做出重大贡献，并扩大他成功的指导计划至关重要。

DESCRIPTION (provided by applicant): Osteoporosis is a significant concern for both older men and women. Recent studies suggest skeletal biomarkers might provide important information about the biologic causes of osteoporosis and may be useful to predict fracture alone or when combined with other risk factors. To extend his ongoing NIH-funded work on biomarkers and skeletal fragility, Dr. Douglas Bauer, Professor of Medicine, Epidemiology & Biostatistics at the University of California, San Francisco, is requesting a renewal of his K24 Midcareer Investigator Award in Patient-Oriented Research with the scientific goals of developing new and clinically useful proteomic biomarkers using data from a well characterized longitudinal cohort of older men (MrOS). Taking advantage of ongoing assessments for fracture and recent funding for proteomic measurements in serum collected at baseline, this study will explore the prospective relationship between proteomic profile and incident vertebral fracture in 3000 MrOS participants. Using these and other data from multiple large studies available through his longstanding affiliation with the San Francisco Coordinating Center, Dr. Bauer will continue to mentor young investigators who are interested in clinical research, particularly residents. With the initial K24 award Dr. Bauer mentored residents and fellows who are now pursuing additional research training and academic careers. In conjunction with the UCSF Clinical and Translational Science Institute, during the initial K24 award he also developed and directed a new comprehensive Resident Research Program. The goal of this novel program is to promote clinical research careers by providing residents with formal instruction in research methods, pilot funding and opportunities to participate in mentored research projects. The continuation of this K24 award is critical to protect Dr. Bauer's time and allow him to continue to make significant contributions towards patient-oriented research related to biomarkers and skeletal fragility and to expand his successful mentoring program.